Colorectal cancer · curated MDI catalog

Molecular tests for colorectal cancer

Colorectal-cancer molecular tests can address very different questions, from screening before diagnosis to treatment profiling and recurrence monitoring. MDI keeps those purposes separate.

41 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • CancerFind — Blood-based multi-cancer early detection assay using methylation, copy-number and fragmentomic features.
  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • CancerNext — Guideline-based germline hereditary cancer panel.
  • CancerNext-Expanded — Germline hereditary-cancer panel; current vendor page reports 78 genes while recent official 77-gene materials require explicit version separation.
  • Cologuard — Stool-based colorectal cancer screening test for average-risk adults.
  • Cologuard Plus — Prescription multitarget stool-based colorectal cancer screening test for average-risk adults age 45 years or older.
  • ColoHealth — Blood-based methylated SEPT9 colorectal cancer testing family; current ColoHealth Direct LDT and historical FDA device lineage are modeled separately.
  • ColoScape — Multiplex plasma cfDNA mutation-and-methylation assay used in colorectal cancer screening-triage and diagnostic-aid contexts.
  • ColoSense — FDA-approved qualitative stool RNA and occult-hemoglobin colorectal cancer screening test for average-risk adults age 45 years or older.
  • COLOTECT CRC Screening — Stool-based colorectal cancer screening test combining DNA methylation and fecal occult blood detection in the current 3.0 configuration.
  • EarlyTect Colon Cancer — Stool DNA methylation test using methylated SDC2 as an aid in colorectal cancer detection.
  • Empower Hereditary Cancer Test — Germline multigene hereditary-cancer test using blood or saliva to assess inherited cancer risk.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • Galleri — Prescription-only multi-cancer early detection test.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Idylla KRAS Mutation Test — European CE-IVD cartridge-based qPCR test for KRAS mutations in colorectal cancer.
  • Idylla MSI Test — Microsatellite-instability molecular diagnostic test for colorectal cancer with jurisdiction-specific IVD/CDx versions.
  • Idylla NRAS-BRAF Mutation Test — European CE-IVD cartridge-based qPCR test for NRAS and BRAF mutations in colorectal cancer.
  • Invitae Hereditary Colorectal Cancer Guidelines-based Panel — NGS germline panel for hereditary colorectal cancer predisposition.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • Labcorp Plasma Detect Genome MRD — Tumor-informed whole-genome sequencing ctDNA MRD test currently offered for stage III colon cancer baseline and monitoring.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • MyRisk — Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • OncoBEAM RAS CRC Kit CE-IVD — CE-IVD plasma ctDNA assay for detection of KRAS and NRAS mutations in colorectal cancer using BEAMing technology.
  • Oncodetect MRD — Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
  • OncoGuide EpiLight Methylation Detection Kit — Real-time PCR epigenomic assay measuring DNA methylation across 16 regions to support treatment selection in colorectal cancer.
  • OncoGuide PlasmaSeq Oncopanel System — Plasma ctDNA targeted sequencing assay for RAS and BRAF V600E alterations used to support treatment selection in colorectal cancer in Japan.
  • OncoSeek — Blood-based multi-cancer diagnostic-aid test combining seven protein tumor markers with age and sex in an AI model that reports cancer probability and likely tissue of origin.
  • OneTest for Cancer — Blood-based multi-cancer early detection LDT combining multiple serum tumor biomarkers with a machine-learning risk algorithm.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • Quest Hereditary Colorectal Cancer Panel — 20-gene germline panel for hereditary colorectal-cancer susceptibility, Quest test code 38631.
  • Shield — Blood-based colorectal cancer screening test.
  • SimpleScreen CRC — FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • SPOT-MAS CRC — Plasma SEPTIN9 DNA methylation test for colorectal cancer early detection.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.
  • therascreen BRAF V600E RGQ PCR Kit — Real-time PCR companion diagnostic for source-scoped BRAF V600E testing in colorectal cancer.
  • therascreen KRAS RGQ PCR Kit — FDA-approved real-time PCR KRAS companion diagnostic for colorectal cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance